Antidote Market Size, Share & Trends Analysis Report By Type (Chemical Antidote, Physical Antidote, Pharmacological Antidote), By Route Of Administration, By Distribution Channel, By End-use, By Region, And Segment Forecasts, 2024 - 2030

Antidote Market Size, Share & Trends Analysis Report By Type (Chemical Antidote, Physical Antidote, Pharmacological Antidote), By Route Of Administration, By Distribution Channel, By End-use, By Region, And Segment Forecasts, 2024 - 2030


Antidote Market Growth & Trends

The global antidote market is expected to reach USD 3.58 billion by 2030, expanding at a CAGR of 7.60% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the incidence of snakebites and the adverse effects associated with them. For instance, according to a research article published on PLOS in 2023, approximately 58,000 deaths were recorded in India due to snake bites.

Moreover, surge in number of drug overdoses is driving the market. According to U.S. Department of Health & Human Services, about 106,699 drug overdose deaths were recorded in the U.S. in 2021. Antidote works to neutralize or reverse the toxic effects of specific drug. For instance, Naloxone is commonly used to reverse respiratory sedation and depression in opioid overdose rapidly. These capabilities of antidote are boosting the market growth.

Furthermore, rising prevalence of occupational poisoning is also contributing to the increased need for antidotes. Applications of antidote is rising owing to the growing incidence of opioid overdose, cyanide poisoning, carbon monoxide poisoning, lead poisoning, and organophosphate poisoning among others. For instance, as per NCBI research article, estimates in December 2020, approximately 385 million instances of unintentional pesticide poisoning occurred across the globe, including 11,000 deaths. Thus, the market is expected to grow rapidly during the forecast period.

Increasing R&D activities, launch, and approval of novel antidote drugs for treating several poisoning cases are anticipated to accelerate the growth during the projected period. For instance, in August 2023, Rising Pharmaceuticals, announced the launch and approval of Edetate calcium disodium injection for treating lead poisoning. In addition, in April 2021, Hikma Pharmaceuticals PLC, received U.S. approval of KLOXXADO TM nasal spray for treating opioid overdose. Such strategic initiatives by the key operating players are expected to boost the market.

Furthermore, a number of awareness activities to spread awareness regarding the identification of toxins aided with government initiatives to increase knowledge of antidotes and drugs is expected to drive the growth of overall market. However, limited availability of antidote due to manufacturing issues, regulatory obstacles, or economic factors can restrict access to life-saving antidotes. High costs of certain antidotes may pose financial barriers. In addition, storage requirements, shelf life limitations, and the need for specialized knowledge and training may restrict the applications of antidote. On the other hand, ongoing research and development efforts aim to improve availability, effectiveness, and safety in managing poisonings and toxic exposures are anticipated to offer lucrative opportunities for the market in the near future.

Antidote Market Report Highlights
  • By type, the chemical antidote dominated the antidote market in 2023 attributable to precise dosing, minimized compilations, and consistent outcomes
  • By route of administration, injectionheld the largest segment share of antidote market 2023, attributable to their rapid action and high specificity
  • By distribution channel, hospital pharmacies dominated the market in 2023. This growth can be attributed to numerous factors, including easy accessibility of antidote through hospital pharmacies
  • By end-use, the hospitals held the largest share in 2023. Increasing number of hospitalizations and treatments in the hospital settings is propelling overall growth
  • North America has established a strong regional position with a 33.57% share in 2023, owing to presence of key operating players, rising incidence of poisoning, and increasing research and development activities in the region
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation
1.1.1. Market Definitions
1.2. Objectives
1.2.1. Objective - 1
1.2.2. Objective - 2
1.2.3. Objective - 3
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Gvr’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. List of Primary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers
3.5. Market Restraint Analysis
3.6. Business Environment Analysis
3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.6.2. Porter’s Five Forces Analysis
3.6.3. COVID-19 Impact Analysis
Chapter 4. Type Business Analysis
4.1. Antidote Market: Type Movement Analysis
4.2. Chemical Antidote
4.2.1. Chemical Antidote Market, 2018 - 2030 (USD Million)
4.3. Physical Antidote
4.3.1. Physical Antidote Market, 2018 - 2030 (USD Million)
4.4. Pharmacological Antidote
4.4.1. Pharmacological Antidote Market, 2018 - 2030 (USD Million)
Chapter 5. Route of Administration Business Analysis
5.1. Antidote Market: Route of Administration Movement Analysis
5.2. Oral
5.2.1. Oral Market, 2018 - 2030 (USD Million)
5.3. Topical
5.3.1. Topical Market, 2018 - 2030 (USD Million)
5.4. Injectable
5.4.1. Injectable Market, 2018 - 2030 (USD Million)
5.5. Others
5.5.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. Distribution Channel Business Analysis
6.1. Antidote Market: Distribution Channel Movement Analysis
6.2. Hospital Pharmacies
6.2.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
6.3. Retail Pharmacies
6.3.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
6.4. Online Pharmacies
6.4.1. Cerebrospinal Fluid Market, 2018 - 2030 (USD Million)
Chapter 7. End Use Business Analysis
7.1. Antidote Market: Distribution Channel Movement Analysis
7.2. Hospitals
7.2.1. Hospitals Market, 2018 - 2030 (USD Million)
7.3. Homecare
7.3.1. Homecare Market, 2018 - 2030 (USD Million)
7.4. Specialty Clinics
7.4.1. Specialty Clinics Market, 2018 - 2030 (USD Million)
7.5. Others
7.5.1. Others Market, 2018 - 2030 (USD Million)
Chapter 8. Regional Business Analysis
8.1. Antidote Market Share By Region, 2023 & 2030
8.2. North America
8.2.1. North America Antidote market, 2018 - 2030 (USD Million)
8.2.2. U.S.
8.2.2.1. Key Country Dynamics
8.2.2.2. Target Disease Prevalence
8.2.2.3. Competitive Scenario
8.2.2.4. Regulatory Framework
8.2.2.5. Reimbursement Scenario
8.2.2.6. U.S. Antidote market, 2018 - 2030 (USD MILLION)
8.2.3. Canada
8.2.3.1. Key Country Dynamics
8.2.3.2. Target Disease Prevalence
8.2.3.3. Competitive Scenario
8.2.3.4. Regulatory Framework
8.2.3.5. Reimbursement Scenario
8.2.3.6. Canada Antidote market, 2018 - 2030 (USD Million)
8.3. Europe
8.3.1. Europe Antidote market, 2018 - 2030 (USD Million)
8.3.2. Germany
8.3.2.1. Key Country Dynamics
8.3.2.2. Target Disease Prevalence
8.3.2.3. Competitive Scenario
8.3.2.4. Regulatory Framework
8.3.2.5. Reimbursement Scenario
8.3.2.6. Germany Antidote market, 2018 - 2030 (USD Million)
8.3.3. UK
8.3.3.1. Key Country Dynamics
8.3.3.2. Target Disease Prevalence
8.3.3.3. Competitive Scenario
8.3.3.4. Regulatory Framework
8.3.3.5. Reimbursement Scenario
8.3.3.6. UK Antidote market, 2018 - 2030 (USD Million)
8.3.4. France
8.3.4.1. Key Country Dynamics
8.3.4.2. Target Disease Prevalence
8.3.4.3. Competitive Scenario
8.3.4.4. Regulatory Framework
8.3.4.5. Reimbursement Scenario
8.3.4.6. France Antidote market, 2018 - 2030 (USD Million)
8.3.5. Italy
8.3.5.1. Key Country Dynamics
8.3.5.2. Target Disease Prevalence
8.3.5.3. Competitive Scenario
8.3.5.4. Regulatory Framework
8.3.5.5. Reimbursement Scenario
8.3.5.6. Italy Antidote market, 2018 - 2030 (USD Million)
8.3.6. Spain
8.3.6.1. Key Country Dynamics
8.3.6.2. Target Disease Prevalence
8.3.6.3. Competitive Scenario
8.3.6.4. Regulatory Framework
8.3.6.5. Reimbursement Scenario
8.3.6.6. Spain Antidote market, 2018 - 2030 (USD Million)
8.3.7. Denmark
8.3.7.1. Key Country Dynamics
8.3.7.2. Target Disease Prevalence
8.3.7.3. Competitive Scenario
8.3.7.4. Regulatory Framework
8.3.7.5. Reimbursement Scenario
8.3.7.6. Denmark Antidote market, 2018 - 2030 (USD Million)
8.3.8. Sweden
8.3.8.1. Key Country Dynamics
8.3.8.2. Target Disease Prevalence
8.3.8.3. Competitive Scenario
8.3.8.4. Regulatory Framework
8.3.8.5. Reimbursement Scenario
8.3.8.6. Sweden Antidote market, 2018 - 2030 (USD Million)
8.3.9. Norway
8.3.9.1. Key Country Dynamics
8.3.9.2. Target Disease Prevalence
8.3.9.3. Competitive Scenario
8.3.9.4. Regulatory Framework
8.3.9.5. Reimbursement Scenario
8.3.9.6. Norway Antidote market, 2018 - 2030 (USD Million)
8.4. Asia Pacific
8.4.1. Asia Pacific Antidote market, 2018 - 2030 (USD Million)
8.4.2. Japan
8.4.2.1. Key Country Dynamics
8.4.2.2. Target Disease Prevalence
8.4.2.3. Competitive Scenario
8.4.2.4. Regulatory Framework
8.4.2.5. Reimbursement Scenario
8.4.2.6. Japan Antidote market, 2018 - 2030 (USD Million)
8.4.3. China
8.4.3.1. Key Country Dynamics
8.4.3.2. Target Disease Prevalence
8.4.3.3. Competitive Scenario
8.4.3.4. Regulatory Framework
8.4.3.5. Reimbursement Scenario
8.4.3.6. China Antidote market, 2018 - 2030 (USD Million)
8.4.4. India
8.4.4.1. Key Country Dynamics
8.4.4.2. Target Disease Prevalence
8.4.4.3. Competitive Scenario
8.4.4.4. Regulatory Framework
8.4.4.5. Reimbursement Scenario
8.4.4.6. India Antidote market, 2018 - 2030 (USD Million)
8.4.5. South Korea
8.4.5.1. Key Country Dynamics
8.4.5.2. Target Disease Prevalence
8.4.5.3. Competitive Scenario
8.4.5.4. Regulatory Framework
8.4.5.5. Reimbursement Scenario
8.4.5.6. South Korea Antidote market, 2018 - 2030 (USD Million)
8.4.6. Australia
8.4.6.1. Key Country Dynamics
8.4.6.2. Target Disease Prevalence
8.4.6.3. Competitive Scenario
8.4.6.4. Regulatory Framework
8.4.6.5. Reimbursement Scenario
8.4.6.6. Australia Antidote market, 2018 - 2030 (USD Million)
8.4.7. Thailand
8.4.7.1. Key Country Dynamics
8.4.7.2. Target Disease Prevalence
8.4.7.3. Competitive Scenario
8.4.7.4. Regulatory Framework
8.4.7.5. Reimbursement Scenario
8.4.7.6. Thailand Antidote market, 2018 - 2030 (USD Million)
8.5. Latin America
8.5.1. Latin America Antidote market, 2018 - 2030 (USD Million)
8.5.2. Brazil
8.5.2.1. Key Country Dynamics
8.5.2.2. Target Disease Prevalence
8.5.2.3. Competitive Scenario
8.5.2.4. Regulatory Framework
8.5.2.5. Reimbursement Scenario
8.5.2.6. Brazil Antidote market, 2018 - 2030 (USD Million)
8.5.3. Mexico
8.5.3.1. Key Country Dynamics
8.5.3.2. Target Disease Prevalence
8.5.3.3. Competitive Scenario
8.5.3.4. Regulatory Framework
8.5.3.5. Reimbursement Scenario
8.5.3.6. Mexico Antidote market, 2018 - 2030 (USD Million)
8.5.4. Argentina
8.5.4.1. Key Country Dynamics
8.5.4.2. Target Disease Prevalence
8.5.4.3. Competitive Scenario
8.5.4.4. Regulatory Framework
8.5.4.5. Reimbursement Scenario
8.5.4.6. Argentina Antidote market, 2018 - 2030 (USD Million)
8.6. MEA
8.6.1. MEA Antidote market, 2018 - 2030 (USD Million)
8.6.2. South Africa
8.6.2.1. Key Country Dynamics
8.6.2.2. Target Disease Prevalence
8.6.2.3. Competitive Scenario
8.6.2.4. Regulatory Framework
8.6.2.5. Reimbursement Scenario
8.6.2.6. South Africa Antidote market, 2018 - 2030 (USD Million)
8.6.3. Saudi Arabia
8.6.3.1. Key Country Dynamics
8.6.3.2. Target Disease Prevalence
8.6.3.3. Competitive Scenario
8.6.3.4. Regulatory Framework
8.6.3.5. Reimbursement Scenario
8.6.3.6. Saudi Arabia Antidote market, 2018 - 2030 (USD Million)
8.6.4. UAE
8.6.4.1. Key Country Dynamics
8.6.4.2. Target Disease Prevalence
8.6.4.3. Competitive Scenario
8.6.4.4. Regulatory Framework
8.6.4.5. Reimbursement Scenario
8.6.4.6. UAE Antidote market, 2018 - 2030 (USD Million)
8.6.5. Kuwait
8.6.5.1. Key Country Dynamics
8.6.5.2. Target Disease Prevalence
8.6.5.3. Competitive Scenario
8.6.5.4. Regulatory Framework
8.6.5.5. Reimbursement Scenario
8.6.5.6. Kuwait Antidote market, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Participant’s overview
9.2. Financial performance
9.3. Participant categorization
9.3.1. Market Leaders
9.3.2. Antidote market Share Analysis, 2023
9.3.3. Company Profiles
9.3.3.1. Pfizer Inc
9.3.3.1.1. Company Overview
9.3.3.1.2. Financial Performance
9.3.3.1.3. Product Benchmarking
9.3.3.1.4. Strategic Initiatives
9.3.3.2. Hikma Pharmaceuticals PLC
9.3.3.2.1. Company Overview
9.3.3.2.2. Financial Performance
9.3.3.2.3. Product Benchmarking
9.3.3.2.4. Strategic Initiatives
9.3.3.3. Dr. Reddy’s Laboratories Ltd
9.3.3.3.1. Company Overview
9.3.3.3.2. Financial Performance
9.3.3.3.3. Product Benchmarking
9.3.3.3.4. Strategic Initiatives
9.3.3.4. Mylan N.V.
9.3.3.4.1. Company Overview
9.3.3.4.2. Financial Performance
9.3.3.4.3. Product Benchmarking
9.3.3.4.4. Strategic Initiatives
9.3.3.5. Fresenius Kabi AG
9.3.3.5.1. Company Overview
9.3.3.5.2. Financial Performance
9.3.3.5.3. Product Benchmarking
9.3.3.5.4. Strategic Initiatives
9.3.3.6. Zydus Lifesciences Ltd
9.3.3.6.1. Company Overview
9.3.3.6.2. Financial Performance
9.3.3.6.3. Product Benchmarking
9.3.3.6.4. Strategic Initiatives
9.3.3.7. Endo International plc
9.3.3.7.1. Company Overview
9.3.3.7.2. Financial Performance
9.3.3.7.3. Product Benchmarking
9.3.3.7.4. Strategic Initiatives
9.3.3.8. Novartis AG
9.3.3.8.1. Company Overview
9.3.3.8.2. Financial Performance
9.3.3.8.3. Product Benchmarking
9.3.3.8.4. Strategic Initiatives
9.3.3.9. Baxter International, Inc.
9.3.3.9.1. Company Overview
9.3.3.9.2. Financial Performance
9.3.3.9.3. Product Benchmarking
9.3.3.9.4. Strategic Initiatives
9.3.3.10. EMERGENT
9.3.3.10.1. Company Overview
9.3.3.10.2. Financial Performance
9.3.3.10.3. Product Benchmarking
9.3.3.10.4. Strategic Initiatives
9.3.4. Strategy Mapping
9.3.4.1. Expansion
9.3.4.2. Acquisition
9.3.4.3. Collaborations
9.3.4.4. Disease Type/Drug Class Launch
9.3.4.5. Partnerships
9.3.4.6. Others

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings